Fill your details to get an instant callback from our experts
The reported results are promising: Over 80% relative bioavailability Around 160 higher bioavailability vs oral tablets Sustained drug levels for ~1 week (once-weekly dosing potential) Additionally, the microneedle patches are stable at room temperature, eliminating the need for cold storage, unlike semaglutide injections
Not reasonable as a physique tool in young men with normal GH
Price 50.00 INR/ Piece Minimum Order Quantity 5000 Pieces Supply Ability 10000000 Pieces Per Day Delivery Time 35 Days Main Domestic Market , All India, South India, Central India, West India, North India, East India, Gujarat, Karnataka, Kerala, Lakshadweep, Mizoram, Meghalaya, Manipur, Andhra Pradesh, Bihar, Chandigarh, Daman and Diu, Goa, Jharkhand, Odisha, Punjab, Assam, Delhi, Dadra and Nagar Haveli, Andaman and Nicobar Islands, Arunachal Pradesh, Chhattisgarh, Haryana, Himachal Pradesh, Jammu and Kashmir, Madhya Pradesh, Maharashtra, Nagaland, Rajasthan, Sikkim, Tamil Nadu, Telangana, Tripura, Pondicherry, Uttar Pradesh, Uttarakhand, West Bengal Main Export Market(s) Asia, Middle East, Africa Price: 50 100 200 250 500 1000+ More Products in Injection Manufacturing (Lyophilized And Liquid) Category Iron Sucrose Injection Price 249 INR / Piece Minimum Order Quantity : 100 Pieces Drug Type : Injection Origin of Medicine : India Dosage : As per suggestion Physical Form : Liquid Carboplatin Injection Price 100.00 INR / Piece Minimum Order Quantity : 50 Pieces Drug Type : Injection Origin of Medicine : India Dosage : As per suggestion Physical Form : Liquid Teicoplanin Injection Price 50 INR / Piece Minimum Order Quantity : 5000 Pieces Drug Type : Injection Origin of Medicine : India Dosage : As per suggestion Physical Form : Liquid Tobramycin Sulphate Injection Price 10.00 INR / Piece Minimum Order Quantity : 5000 Pieces Drug Type : Injection Origin of Medicine : India Dosage : As per suggestion Physical Form : Liquid
doi:10.1016/j.molmet.2016.04.007 171
Proposals were advanced to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, further limiting large-scale production
